Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    OtherPreclinical

    B7-33 Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about B7-33 dosing: protocols and safety.

    Dose Range

    500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.

    Frequency

    Once daily or every other day, subcutaneous (community practice only). B7-33 has a very short half-life; no validated human dosing schedule exists.

    Cycle Length

    Typically 4-12 weeks on with 4-8 week off-periods between cycles (community convention; not clinically validated).

    Half-Life

    In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588).

    Dosage Calculator

    Calculate exact dosing for B7-33.

    Dosing Protocols

    Beginner

    A defensible beginner protocol for B7-33 begins with a clear-eyed assessment of whether you are an appropriate user. B7-33 targets cardiovascular biology and could affect blood pressure, renal function, and cardiac hemodynamics. Ideal beginner users have documented cardiovascular risk factors or early cardiometabolic disease, established medical care with a physician who knows about the compound, baseline labs and cardiovascular assessment, stable medications, and realistic expectations. Users with advanced heart failure, uncontrolled hypertension, recent myocardial infarction, severe renal disease, or other acute cardiovascular concerns should pursue established medical treatment and not use B7-33 as an experimental alternative. Users with no cardiovascular disease who are using B7-33 for general longevity or anti-fibrotic effects have a different risk calculus but should still maintain baseline monitoring and physician involvement. Baseline assessment for a beginner B7-33 cycle: comprehensive metabolic panel (creatinine, eGFR, electrolytes, glucose, liver enzymes); CBC with differential; lipid panel with ApoB and Lp(a); HbA1c and fasting insulin; BNP or NT-proBNP (natriuretic peptides for cardiac function); resting blood pressure (averaged across multiple measurements); resting ECG; echocardiogram if cardiac pathology is suspected; and age-appropriate cancer screening current. Baseline labs should be within 1-3 months before initiating a cycle. A conservative beginner dose of B7-33 from self-report community reports is 500-1000 micrograms per injection administered subcutaneously once daily or every other day. These doses are empirical extrapolations from rodent pharmacology and have no clinical validation. Beginners should start at the low end (500 mcg daily or every other day) and hold at the starting dose for at least 2-3 weeks before any titration to allow time for early effects and adverse effects to emerge. Cycle duration for beginners is typically 4-6 weeks of continuous daily or every-other-day dosing, followed by a break of at least 4-8 weeks before any repeat cycle. The break provides time for any acute hemodynamic effects to resolve, for subjective and objective markers to return to baseline, and for clean interpretation of whether the compound produced durable changes during the cycle. Route of administration for self-experimenters is overwhelmingly subcutaneous, using insulin syringes (28-31 gauge) into abdominal fat, thigh, or upper arm. Subcutaneous dosing provides adequate bioavailability for the peptide and is the safest self-administration route. Intravenous administration was used in serelaxin clinical trials but is not appropriate for self-administration. Intramuscular administration has been reported but provides no documented advantage for this peptide over subcutaneous delivery. Timing of administration within the day is typically morning, particularly when blood pressure effects are a concern — morning dosing allows for monitoring through the day when the user is active and alert, rather than during sleep when symptomatic hypotension might go undetected. Monitoring during a beginner cycle should include: daily blood pressure measurements (home cuff) with readings at consistent times; tracking of any subjective symptoms (lightheadedness, fatigue, shortness of breath, edema, mood changes, sleep changes); mid-cycle labs (week 2-3) to check renal function and electrolytes; end-of-cycle labs (week 4-6) including full panels and cardiac markers; and post-break labs (2-4 weeks after stopping) to characterize whether effects persist. Exercise tolerance and activity patterns should be tracked because they are sensitive to cardiovascular effects. Users with fitness trackers should note any changes in resting heart rate, HRV, and exercise performance. Decision framework after one beginner cycle: if the cycle produced clearly adverse effects (symptomatic hypotension, worsening renal function, concerning cardiac symptoms, unusual injection reactions), stop and do not continue; if the cycle produced no detectable effects on monitored markers or subjective outcomes, reconsider whether continued use is justified; if the cycle produced favorable trends on cardiovascular markers (BP, BNP, echocardiographic measures if available) without adverse effects, cautious continuation with additional cycles is reasonable. The beginner protocol specifically avoids the common mistake of treating diagnosed cardiovascular disease with research-chemical B7-33 as a substitute for established therapy. Users should not use B7-33 in place of ACE inhibitors, beta blockers, SGLT2 inhibitors, or other validated heart failure treatments. The potential niche for B7-33 is as an experimental adjunct to optimized medical therapy in patients with specific cardiovascular concerns, or as a general cardioprotective experiment in otherwise healthy users with specific risk profiles. It is not a substitute for cardiology-directed care.

    Standard

    Intermediate B7-33 users have completed one or more beginner cycles without significant adverse effects, have established confidence in their vendor and batch quality, and are considering longer cycles, higher doses, or specific indication-focused protocols. An intermediate approach typically involves 1000-2000 micrograms per injection subcutaneously daily or every other day for 6-10 week cycles with 4-8 week off-periods between. The higher dose range is intended to extract larger effect sizes on cardiovascular and fibrotic markers on the assumption that beginner doses may be subtherapeutic; this assumption is empirically driven rather than clinically validated. Intermediate users often introduce combinations with other cardioprotective or anti-fibrotic peptides. Common combinations include B7-33 with BPC-157 and TB-500 for broader tissue support, or with Humanin or MOTS-c for additional mitochondrial cardioprotection. More ambitious combinations may add GH secretagogues, mitochondrial support compounds, or metabolic interventions. Each added compound introduces attribution loss and risk stacking; the cleaner approach is adding one new compound at a time. Monitoring at the intermediate level expands on beginner monitoring with more frequent and comprehensive assessments. Monthly or bimonthly labs during active cycles: CMP, CBC with differential, lipid panel with ApoB and Lp(a), HbA1c, fasting insulin, BNP/NT-proBNP, thyroid panel, hs-CRP, electrolytes, and kidney function markers. Cardiovascular monitoring: daily home blood pressure readings, resting heart rate trending via wearable, at least one ECG during each cycle, and consideration of echocardiogram every 6-12 months to track cardiac structural and functional changes. Imaging considerations: coronary calcium score at baseline for users over 40 with cardiovascular risk factors; carotid intima-media thickness for vascular health tracking; DEXA body composition to track fat and lean mass changes that may reflect cardiovascular benefit. Functional assessments: 6-minute walk test for exercise tolerance if clinically relevant; maximal exercise testing if available for more sensitive cardiovascular evaluation; specific functional assessments relevant to the user's indication. Intermediate users should have deepening clinical infrastructure: a cardiologist who knows about the compound (or is willing to learn), regular follow-up with ability to order specialized tests and imaging, and a plan for escalating care if concerning findings emerge. For users with diagnosed cardiovascular disease, the cardiologist involvement is essential and not replaceable by self-monitoring. Cost at the intermediate stage is meaningful. Research-chemical B7-33 typically costs $40-$100 per vial (usually 5 mg), and a 10-week cycle at 1000 mcg daily uses 70 mg of peptide, costing $560-$1,400 per cycle depending on source. Two cycles per year runs $1,120-$2,800 annually just for the peptide. Adding stacked compounds, labs, imaging, and specialty consultation visits increases the annual cost substantially. Users should evaluate whether the observed benefits justify this expenditure relative to optimizing validated medical therapy, lifestyle interventions, and evidence-based preventive care that would typically have higher ROI for cardiovascular outcomes. Users who have cycled B7-33 at the intermediate level without clear benefit should strongly consider discontinuing rather than escalating to advanced protocols. The discipline of stopping when the experiment is not working is a key protective factor against escalating research-chemical use without corresponding benefit. Users should also be alert to changes that could be subtle but meaningful: gradual changes in exercise tolerance, subtle shifts in blood pressure patterns, small changes in lab markers that could indicate early adaptation or maladaptation to the compound. Pattern recognition across multiple cycles and years is more informative than single-cycle interpretations.

    Advanced

    Advanced B7-33 protocols are used by experienced self-experimenters who have completed multiple intermediate cycles with documented positive response and no concerning adverse effects, who have robust clinical infrastructure, and who are integrating B7-33 into comprehensive cardiometabolic or longevity protocols. Advanced dosing can involve 2000-4000 micrograms per injection subcutaneously daily for 8-12 week cycles with 4-8 week off-periods, or in some cases continuous dosing with quarterly breaks. There is no published clinical evidence that higher doses produce proportionally better outcomes, and advanced dose ranges primarily increase cumulative exposure and cost without documented additional benefit. The advanced protocol question is less about dose escalation and more about integration within sophisticated cardiometabolic and longevity stacks. A typical advanced cardiometabolic stack built around B7-33 might include: B7-33 at 2000 mcg daily for anti-fibrotic cardiovascular support; optimized pharmacologic therapy for cardiovascular conditions (ACE inhibitor or ARB, beta blocker if indicated, SGLT2 inhibitor, statin, other medications as individually indicated); Semaglutide or Tirzepatide for metabolic management; Humanin or MOTS-c for mitochondrial cardioprotection; 5-Amino-1MQ for NNMT inhibition; BPC-157 and TB-500 for tissue support; and comprehensive supplementation with omega-3s, coenzyme Q10, magnesium, and condition-specific nutrients. Advanced longevity stacks may add Epithalon for telomere support, Thymosin Alpha-1 for immune modulation, FOXO4-DRI pulses for senolytic effects, and other longevity-oriented compounds. These comprehensive stacks represent the cutting edge of research-chemical self-experimentation and carry substantially all of the attribution-loss and risk-stacking concerns that apply to complex multi-compound protocols. Monitoring at the advanced level should be extensive and ongoing. Monthly labs during active cycles and quarterly during off-cycles: full CMP with GGT and alkaline phosphatase; CBC with differential and reticulocyte count; comprehensive lipid panel with ApoB, Lp(a), LDL-P, and HDL subparticles; BNP or NT-proBNP; high-sensitivity troponin if available; thyroid panel with reverse T3; full hormone panel; inflammatory markers (hs-CRP, IL-6, fibrinogen); iron studies; homocysteine; complete nutrient panel. Specialty testing every 6-12 months: biological age testing (DNA methylation clocks), inflammatory cytokine panels, oxidative stress markers. Annual comprehensive imaging: coronary calcium score or CT coronary angiography; carotid ultrasound; echocardiogram with strain imaging; DEXA body composition and bone density. Functional assessments: VO2max testing (gold standard for aerobic capacity), 6-minute walk test, maximal exercise testing, grip strength, timed chair rise tests. Continuous monitoring via consumer wearables for resting heart rate, HRV, sleep architecture, activity, and blood pressure. The purpose of this monitoring intensity is early detection of subclinical abnormalities and providing data for protocol adjustment. Advanced users should develop clear decision criteria: specific lab thresholds that would trigger pause or stop; subjective symptom patterns that warrant evaluation; imaging findings that would prompt cardiology consultation. Pre-committed criteria make it easier to make rational decisions when ambiguous data arrive. The advanced B7-33 user is positioned to contribute to the broader knowledge base by sharing anonymized personal data in structured n=1 experiments with thoughtful design. This is not a substitute for clinical trials but is better than anecdote-driven community discussion. Advanced users should plan protocol exit. Cardiovascular interventions do not need to be continued indefinitely, and if markers are optimized and lifestyle is supporting health, pharmacologic complexity can be reduced. Planned de-escalation removing the lowest-value compounds first is a rational strategy. The goal of cardiovascular health is sustained function over decades, not maximum peptide stacking complexity. The overall theme of the advanced B7-33 protocol is that sophistication and monitoring can be escalated but the underlying evidence base remains limited to preclinical data and rodent efficacy, attribution in multi-compound stacks becomes impossible, and sophistication does not compensate for absence of clinical trial validation.

    Commonly Stacked With

    B7-33 sits in the cardioprotective and anti-fibrotic peptide category and pairs mechanistically with other interventions targeting cardiovascular health, fibrotic disease, and broader organ protection. The stacking framework depends on the user's specific health context — whether they are using B7-33 for cardioprotection without specific cardiac pathology, for managing diagnosed cardiovascular disease, for anti-fibrotic effects in specific tissues, or as part of a general longevity and peptide protocol — because the rational combinations differ across these applications. Start with established cardiovascular medications if relevant. Users with diagnosed cardiovascular disease who are considering B7-33 as an experimental adjunct should maintain their established medications (ACE inhibitors, ARBs, beta blockers, statins, SGLT2 inhibitors, GLP-1 agonists as individually indicated) and should not consider B7-33 as a substitute for validated therapy. The potential value of B7-33 in this context is as an add-on to optimized medical therapy, not as a replacement. Users should also coordinate B7-33 use with their cardiologist and have ongoing follow-up that can detect any adverse effects or medication interactions. With GLP-1 receptor agonists — Semaglutide, Tirzepatide, Retatrutide, Mazdutide — the combination addresses complementary aspects of cardiometabolic disease. GLP-1 agonists produce weight loss, improved glycemic control, and direct cardiovascular benefits that have been established in large Phase 3 trials. B7-33 addresses anti-fibrotic and cardioprotective pathways through a different mechanism. The theoretical combination is attractive for patients with cardiometabolic syndrome and early heart failure with preserved ejection fraction (HFpEF) where fibrosis plays a significant role. No clinical evidence supports the combination specifically, but the mechanistic rationale is coherent. With other cardioprotective peptides — Humanin, MOTS-c, SS-31 — the combination provides multi-mechanism cardioprotection. Humanin's cytoprotective effects through STAT3 and Bax sequestration complement B7-33's anti-fibrotic effects through biased RXFP1 activation. Clinical evidence for combinations is absent, but the mechanistic diversification may be appealing for users pursuing comprehensive cardiovascular support. With BPC-157 and TB-500 — both of which have broad tissue-protective and anti-inflammatory effects — the combination provides tissue-repair and anti-fibrotic coverage. Users pursuing recovery from cardiac injury, post-surgical recovery with cardiac involvement, or general connective tissue health use this combination in biohacker protocols. No clinical validation exists. With anti-inflammatory interventions — KPV for gut inflammation, Thymosin Alpha-1 for immune modulation, CCK-8 and other gut peptides — combinations have been used in comprehensive anti-inflammatory and longevity stacks. No clinical data support specific combinations. With metabolic interventions — 5-Amino-1MQ, NAD+, metformin, SGLT2 inhibitors — the combination addresses metabolic drivers of cardiovascular disease through complementary mechanisms. Relaxin has its own effects on glucose metabolism and insulin sensitivity that are not fully characterized, but adding metabolic interventions to B7-33 is not contraindicated on mechanistic grounds. With GH secretagogues — CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 — combinations are common in peptide protocols. GH/IGF-1 has its own effects on cardiac hypertrophy and fibrosis that are complex and partially opposing to relaxin's anti-fibrotic effects. Patients with cardiac disease should consider whether GH secretagogue use and B7-33 use are mechanistically coherent; the combination is not straightforward. With nitrates and nitric oxide modulators (L-citrulline, L-arginine, organic nitrates), the combination could produce additive vasodilation and hypotension. Users should monitor blood pressure closely and may need to adjust doses or discontinue NO-modulating supplements during B7-33 cycles. With anticoagulants and antiplatelet agents (warfarin, direct oral anticoagulants, aspirin, clopidogrel), B7-33 does not have documented direct anticoagulant effects, but any agent affecting endothelial function could theoretically interact with coagulation cascade regulation. Users on these medications should monitor for bleeding and clotting abnormalities. With lifestyle interventions — regular aerobic and resistance exercise, dietary patterns supporting cardiovascular health (Mediterranean, DASH), weight management, sleep optimization, stress management — these are the foundational layer for any cardiovascular intervention and should be optimized before adding experimental pharmacology. B7-33 used without attention to lifestyle factors in someone with poor cardiometabolic health is unlikely to produce meaningful benefits even if the peptide has intrinsic efficacy. The overall framing is that B7-33 stacks sensibly with other cardioprotective and anti-fibrotic interventions on mechanistic grounds, should be used as an add-on to optimized validated therapy for patients with cardiovascular disease, and belongs in a stack only after lifestyle and established medical therapy are in place. Complex multi-peptide stacks that include B7-33 should be approached with awareness of attribution loss and the difficulty of assigning specific benefits or adverse effects to specific compounds in combination.

    Side Effects & Safety

    The side effect profile of B7-33 in humans is undocumented because no clinical trials have been conducted. Rodent studies from published preclinical work report generally acceptable tolerability at therapeutically effective doses, without overt toxicity on standard endpoints including body weight, behavior, major organ histology, and plasma chemistry. The rodent tolerability picture is limited by the usual preclinical research caveats: studies are short-duration, doses are specific to rodent physiology and route of administration, adverse effects at lower frequency or longer timescales are not captured, and comprehensive toxicology evaluation has not been conducted in the published literature. The most informative clinical data on relaxin-class side effects come from the serelaxin clinical program, which enrolled thousands of patients across multiple Phase 2 and Phase 3 trials and characterized the safety profile of recombinant H2 relaxin at doses producing hemodynamic and symptomatic effects in acute heart failure. Serelaxin was generally well-tolerated in these trials, with the main adverse effects being hypotension (related to the vasodilatory effects), worsening renal function (occasional), and injection-site reactions from the IV infusion. There were no major safety signals that prevented continued development; the program ended because of inadequate efficacy, not safety concerns. Whether B7-33 would have a similar safety profile is uncertain — biased agonism could theoretically produce different side effect patterns than full RXFP1 activation, and the single-chain peptide could have different PK and tissue distribution than recombinant two-chain relaxin. The major theoretical side effect concerns with B7-33 follow from its mechanism as a vasodilatory and anti-fibrotic agent. Hypotension is the most predictable acute effect — RXFP1 activation produces vasodilation through NO-mediated smooth muscle relaxation, and any agent that activates this pathway can produce dose-related reductions in blood pressure. Patients with baseline hypotension, volume depletion, or on antihypertensive medications could experience significant or symptomatic hypotension during dosing. Users should monitor blood pressure during initiation of dosing, especially if they are on blood pressure medications, have baseline low blood pressure, or are volume-depleted from diuretic use or dietary restriction. Renal effects are of concern because of the known effects of relaxin on renal hemodynamics. Relaxin produces a pattern of renal vasodilation, increased glomerular filtration rate, and altered renal blood flow that is beneficial in some contexts (pregnancy, certain cardiovascular conditions) but can be destabilizing in patients with baseline renal dysfunction. In the serelaxin program, worsening renal function was observed in some patients, though generally not severe or sustained. B7-33 users should be alert to signs of renal stress (changes in creatinine, blood urea nitrogen, urine output, urine color) and should establish baseline renal function before starting a cycle. Effects on fibrotic tissues beyond the intended targets are theoretically possible. RXFP1 is expressed in multiple tissues including skin, lung, intestine, and reproductive tissues, and pharmacologic activation of RXFP1 produces anti-fibrotic effects wherever the receptor is engaged. For most users, this broad distribution is a feature rather than a bug — anti-fibrotic effects in lungs, liver, or other tissues may provide additional therapeutic benefit. However, in specific contexts where fibrosis is physiologically protective (wound healing, tissue repair after injury), pharmacologic suppression of fibrotic responses could theoretically delay or impair normal tissue recovery. Users in active post-surgical recovery, healing from significant injury, or with specific conditions involving acute-phase fibrotic responses should consider whether RXFP1 agonism is contextually appropriate. Reproductive and endocrine effects are theoretical concerns because relaxin is naturally a pregnancy-associated hormone with effects on the female reproductive tract, mammary tissue, and systemic cardiovascular physiology during pregnancy. Chronic pharmacologic RXFP1 activation outside of pregnancy context has not been well-characterized for effects on menstrual cycling, fertility, or hormonal homeostasis. Men using B7-33 similarly have not had reproductive effects characterized, and RXFP1 expression in testicular and prostate tissue could theoretically contribute to effects on reproductive function. Anti-fibrotic effects on joint capsules, tendons, and ligaments are of interest because relaxin famously increases joint laxity during pregnancy in support of pelvic changes for childbirth. Users on B7-33 could theoretically experience increased joint laxity, increased susceptibility to joint injury during athletic activity, or changes in connective tissue properties. Athletes using B7-33 should be aware of this potential effect and adjust training accordingly during and after cycles. Injection-related effects include typical subcutaneous peptide injection reactions (redness, swelling, occasional bruising at the injection site) which are common and typically mild. Acute hypersensitivity reactions are rare but possible with any exogenous peptide and warrant immediate medical attention if they occur. Supply-chain quality issues with research-chemical B7-33 include potential impurities, endotoxin contamination, and content variability. Pyrogen contamination can produce flu-like symptoms that may be attributed to the peptide when actually reflecting batch-specific contamination issues. Drug-drug interactions are not characterized. Theoretical interactions include: antihypertensive medications (ACE inhibitors, ARBs, beta blockers, calcium channel blockers, diuretics) where additive hypotensive effects could produce symptomatic hypotension; diuretics where altered renal hemodynamics could interact with volume status; other vasodilators (nitrates, hydralazine) for similar reasons; and anticoagulants where possible effects on endothelial function and coagulation have not been characterized. Users on cardiovascular medications should monitor closely and may need medication adjustment during cycles. Long-term safety of B7-33 is completely unknown. No data exist on effects of chronic or repeated B7-33 exposure over years or decades, and the theoretical profile includes both favorable effects (sustained anti-fibrotic activity in tissues prone to fibrosis with age) and unknown concerns (effects on tissue remodeling during normal healing and repair). Conservative use patterns involve defined cycles with clear start and stop points rather than indefinite continuous use.

    Contraindications

    B7-33's mechanism as a vasodilatory and anti-fibrotic peptide creates a specific contraindication profile reflecting cardiovascular, renal, reproductive, and interaction concerns. Acute cardiovascular instability is an absolute contraindication. Recent myocardial infarction (within 6 weeks), unstable angina, cardiogenic shock, severe aortic stenosis, hypertrophic cardiomyopathy with outflow obstruction, or significant uncorrected cardiac arrhythmias should not be exposed to vasodilatory therapy without intensive care settings. Decompensated heart failure requires active medical management and is not an appropriate context for adding research-chemical peptides. Baseline hypotension (systolic blood pressure below 100 mmHg consistently, or symptomatic orthostatic hypotension) is a relative to absolute contraindication because B7-33's vasodilatory effects would be expected to produce symptomatic hypotension at therapeutic doses. Users with low baseline blood pressure should address volume status and consider whether B7-33 is an appropriate experimental choice. Volume depletion from recent diuresis, dehydration, or dietary restriction warrants replenishment before initiating a cycle. Severe renal disease (eGFR below 30 mL/min/1.73m², advanced chronic kidney disease, or acute kidney injury) is a relative to absolute contraindication because altered renal hemodynamics from RXFP1 activation could destabilize tenuous renal function. Patients with significant renal dysfunction should consult nephrology before any experimental intervention. Pregnancy is a nuanced contraindication. Relaxin is a naturally pregnancy-associated hormone, and exogenous RXFP1 activation during pregnancy could theoretically amplify normal pregnancy physiology (systemic vasodilation, cardiovascular changes, joint laxity) in ways that may not be beneficial. The safety of pharmacologic relaxin-class therapy during pregnancy has not been established. Self-administered B7-33 is not appropriate during pregnancy. Breastfeeding is similarly contraindicated because peptide transfer to breast milk and effects on neonatal physiology are uncharacterized. Women trying to conceive should discontinue B7-33 at least 2-4 weeks before attempting conception. Children and adolescents should not use B7-33 because effects on growth, development, and cardiovascular maturation during this life stage are uncharacterized. Active cancer is a relative contraindication because relaxin signaling has been implicated in some tumor biology in complex ways, with RXFP1 expression on some cancer cells and effects on tumor angiogenesis and metastasis that are not fully characterized. Users with cancer history should consult with oncology before use. Severe autoimmune disease on systemic immunomodulatory therapy is a relative contraindication because effects on immune signaling and inflammatory cascades are uncharacterized. Users with rheumatoid arthritis, lupus, inflammatory bowel disease, or other significant autoimmune conditions should discuss with their specialist. Severe hepatic impairment warrants caution because peptide clearance may be altered, though peptides are typically less dependent on hepatic metabolism than small molecules. Bleeding disorders or active anticoagulation are relative contraindications for any injected therapy because of injection-site bleeding risk, not absolute contraindications. Users on warfarin, direct oral anticoagulants, or antiplatelet therapy should apply pressure after injection and watch for persistent bleeding. Known hypersensitivity to peptide products or to any component of the preparation (including bacteriostatic water preservative) is an absolute contraindication. Drug-drug interactions are characterized primarily theoretically because no human interaction studies of B7-33 exist. Theoretical concerns include: antihypertensive medications (ACE inhibitors, ARBs, beta blockers, calcium channel blockers, alpha blockers, diuretics) where additive hypotensive effects could produce symptomatic hypotension; diuretics in particular where volume depletion combined with vasodilation could be problematic; other vasodilators (nitrates, hydralazine, sildenafil and other PDE5 inhibitors) for similar reasons; immunosuppressants where effects on inflammatory signaling could interact with immunomodulation; PDE5 inhibitors for erectile dysfunction where combined vasodilatory effects could produce significant hypotension; and systemic corticosteroids where effects on tissue remodeling could interact with anti-fibrotic effects. Users on complex cardiovascular regimens should discuss B7-33 with their cardiologist and pharmacist before use. NSAIDs and other medications that affect renal hemodynamics could interact with B7-33's renal effects and warrant attention. The final and most important contraindication is the absence of adequate clinical oversight. Self-experimentation with an unvalidated cardiovascular peptide without a knowledgeable physician who can monitor response and evaluate adverse events does not meet the minimum safety standard for B7-33's risk profile. This is not a specific medical contraindication — it is an infrastructure contraindication that applies regardless of individual health status. Finding a physician with expertise in experimental cardiovascular pharmacology is difficult but possible; the effort is worth more than the peptide itself.

    Check interactions with the Interaction Checker →

    Additional Notes

    B7-33 dosing for self-experimenters is extrapolated from rodent pharmacology and self-report community patterns rather than validated clinical data. Typical dose ranges — 500-1000 mcg for beginners, 1000-2000 mcg for intermediate users, 2000-4000 mcg for advanced users — are empirical and have no clinical validation in humans. The most commonly reported single dose from self-report communities is 1000 micrograms (1 mg) once daily subcutaneously. Cycle structure is continuous daily or every-other-day dosing for 4-12 weeks with 4-8 week off-periods between cycles. The pulsed cycling pattern reflects research-chemical community conventions. Route of administration for self-experimenters is overwhelmingly subcutaneous, using insulin syringes (28-31 gauge) into abdominal fat, thigh, or upper arm. Subcutaneous dosing provides adequate bioavailability, is the safest self-administration route, and avoids the acute risks of intravenous delivery. In the serelaxin clinical program, recombinant H2 relaxin was administered by continuous intravenous infusion for 48 hours, which is not appropriate for self-administration. Intramuscular injection has been used for some peptides but provides no documented advantage for B7-33 over subcutaneous dosing. Oral administration would not be expected to work because the peptide would be degraded in the GI tract. Timing of administration within the day is typically morning, which allows for post-dose monitoring during waking hours when symptomatic hypotension would be apparent. Users with orthostatic symptoms or baseline blood pressure concerns should be especially attentive to timing and should consider having a bottle of electrolyte-containing fluids available at first dosing. Dosing frequency — daily versus every other day — reflects pharmacokinetic considerations. B7-33 has a plasma half-life of approximately minutes to an hour in rodent studies, which is short enough that daily or twice-daily dosing may be needed for sustained effect. However, downstream effects on fibrotic gene expression and tissue remodeling operate on timescales of days to weeks, and less frequent dosing may be sufficient for these effects. The optimal dosing interval has not been empirically established in humans. Human pharmacokinetics of B7-33 are not published. Rodent data suggest rapid clearance consistent with short peptide metabolism. Tissue distribution includes cardiovascular and renal tissues based on RXFP1 expression patterns. Bioavailability after subcutaneous administration is assumed to be reasonable for a peptide of this size but has not been directly measured in humans. Body weight adjustments are typically not made in self-administered protocols. If scaling were applied, it would be approximately 10-50 mcg/kg per dose across the typical range. Missed doses within a cycle can be skipped or taken when remembered; single missed doses are unlikely to affect overall biological exposure meaningfully. Overdose risk from B7-33 is primarily hemodynamic — large doses could produce significant hypotension, bradycardia, and related cardiovascular symptoms. Management of acute overdose would be supportive with fluid resuscitation and cardiovascular support as needed. There is no specific antidote. Quality of the peptide supply is the most variable element. Research-peptide vendors vary significantly in purity, content accuracy, and manufacturing standards. Key quality signals: published third-party analytical testing (HPLC and LC-MS); reasonable market pricing; verified business presence; positive community reputation; and willingness to provide certificates of analysis. B7-33 is a 26-amino-acid peptide that is more complex to synthesize accurately than shorter peptides, and vendors with inadequate synthesis capabilities may produce truncated or incorrect products. Content below 95% purity warrants skepticism about the specific batch. Storage of lyophilized peptide powder is in the freezer in the sealed vial. Reconstituted peptide in bacteriostatic water is refrigerated and used within 2-4 weeks. Signs of degradation include cloudiness, color changes, or visible particulates, and any of these warrant discarding the vial.

    Frequently Asked Questions

    What is the recommended B7-33 dosage?

    The typical dose range for B7-33 is 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.. It is usually administered Once daily or every other day, subcutaneous (community practice only). B7-33 has a very short half-life; no validated human dosing schedule exists.. Always start with the lowest effective dose.

    How often should I take B7-33?

    Once daily or every other day, subcutaneous (community practice only). B7-33 has a very short half-life; no validated human dosing schedule exists.

    Does B7-33 need to be cycled?

    Yes, typical cycle length is Typically 4-12 weeks on with 4-8 week off-periods between cycles (community convention; not clinically validated)..

    What are B7-33 side effects?

    The side effect profile of B7-33 in humans is undocumented because no clinical trials have been conducted. Rodent studies from published preclinical work report generally acceptable tolerability at therapeutically effective doses, without overt toxicity on standard endpoints including body weight, behavior, major organ histology, and plasma chemistry. The rodent tolerability picture is limited by the usual preclinical research caveats: studies are short-duration, doses are specific to rodent physiology and route of administration, adverse effects at lower frequency or longer timescales are not captured, and comprehensive toxicology evaluation has not been conducted in the published literature. The most informative clinical data on relaxin-class side effects come from the serelaxin clinical program, which enrolled thousands of patients across multiple Phase 2 and Phase 3 trials and characterized the safety profile of recombinant H2 relaxin at doses producing hemodynamic and symptomatic effects in acute heart failure. Serelaxin was generally well-tolerated in these trials, with the main adverse effects being hypotension (related to the vasodilatory effects), worsening renal function (occasional), and injection-site reactions from the IV infusion. There were no major safety signals that prevented continued development; the program ended because of inadequate efficacy, not safety concerns. Whether B7-33 would have a similar safety profile is uncertain — biased agonism could theoretically produce different side effect patterns than full RXFP1 activation, and the single-chain peptide could have different PK and tissue distribution than recombinant two-chain relaxin. The major theoretical side effect concerns with B7-33 follow from its mechanism as a vasodilatory and anti-fibrotic agent. Hypotension is the most predictable acute effect — RXFP1 activation produces vasodilation through NO-mediated smooth muscle relaxation, and any agent that activates this pathway can produce dose-related reductions in blood pressure. Patients with baseline hypotension, volume depletion, or on antihypertensive medications could experience significant or symptomatic hypotension during dosing. Users should monitor blood pressure during initiation of dosing, especially if they are on blood pressure medications, have baseline low blood pressure, or are volume-depleted from diuretic use or dietary restriction. Renal effects are of concern because of the known effects of relaxin on renal hemodynamics. Relaxin produces a pattern of renal vasodilation, increased glomerular filtration rate, and altered renal blood flow that is beneficial in some contexts (pregnancy, certain cardiovascular conditions) but can be destabilizing in patients with baseline renal dysfunction. In the serelaxin program, worsening renal function was observed in some patients, though generally not severe or sustained. B7-33 users should be alert to signs of renal stress (changes in creatinine, blood urea nitrogen, urine output, urine color) and should establish baseline renal function before starting a cycle. Effects on fibrotic tissues beyond the intended targets are theoretically possible. RXFP1 is expressed in multiple tissues including skin, lung, intestine, and reproductive tissues, and pharmacologic activation of RXFP1 produces anti-fibrotic effects wherever the receptor is engaged. For most users, this broad distribution is a feature rather than a bug — anti-fibrotic effects in lungs, liver, or other tissues may provide additional therapeutic benefit. However, in specific contexts where fibrosis is physiologically protective (wound healing, tissue repair after injury), pharmacologic suppression of fibrotic responses could theoretically delay or impair normal tissue recovery. Users in active post-surgical recovery, healing from significant injury, or with specific conditions involving acute-phase fibrotic responses should consider whether RXFP1 agonism is contextually appropriate. Reproductive and endocrine effects are theoretical concerns because relaxin is naturally a pregnancy-associated hormone with effects on the female reproductive tract, mammary tissue, and systemic cardiovascular physiology during pregnancy. Chronic pharmacologic RXFP1 activation outside of pregnancy context has not been well-characterized for effects on menstrual cycling, fertility, or hormonal homeostasis. Men using B7-33 similarly have not had reproductive effects characterized, and RXFP1 expression in testicular and prostate tissue could theoretically contribute to effects on reproductive function. Anti-fibrotic effects on joint capsules, tendons, and ligaments are of interest because relaxin famously increases joint laxity during pregnancy in support of pelvic changes for childbirth. Users on B7-33 could theoretically experience increased joint laxity, increased susceptibility to joint injury during athletic activity, or changes in connective tissue properties. Athletes using B7-33 should be aware of this potential effect and adjust training accordingly during and after cycles. Injection-related effects include typical subcutaneous peptide injection reactions (redness, swelling, occasional bruising at the injection site) which are common and typically mild. Acute hypersensitivity reactions are rare but possible with any exogenous peptide and warrant immediate medical attention if they occur. Supply-chain quality issues with research-chemical B7-33 include potential impurities, endotoxin contamination, and content variability. Pyrogen contamination can produce flu-like symptoms that may be attributed to the peptide when actually reflecting batch-specific contamination issues. Drug-drug interactions are not characterized. Theoretical interactions include: antihypertensive medications (ACE inhibitors, ARBs, beta blockers, calcium channel blockers, diuretics) where additive hypotensive effects could produce symptomatic hypotension; diuretics where altered renal hemodynamics could interact with volume status; other vasodilators (nitrates, hydralazine) for similar reasons; and anticoagulants where possible effects on endothelial function and coagulation have not been characterized. Users on cardiovascular medications should monitor closely and may need medication adjustment during cycles. Long-term safety of B7-33 is completely unknown. No data exist on effects of chronic or repeated B7-33 exposure over years or decades, and the theoretical profile includes both favorable effects (sustained anti-fibrotic activity in tissues prone to fibrosis with age) and unknown concerns (effects on tissue remodeling during normal healing and repair). Conservative use patterns involve defined cycles with clear start and stop points rather than indefinite continuous use.

    Where can I buy B7-33?

    Compare 1 listings from 1 vendor on our price comparison page, starting from $42.80.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free